Aliases & Classifications for Connective Tissue Disease

Aliases & Descriptions for Connective Tissue Disease:

Name: Connective Tissue Disease 12 14
Connective Tissue Diseases 52 42 69
Disorder of Connective Tissue 12 29
Connective Tissue Disorders 41
Connective Tissue Disorder 12

External Ids:

Disease Ontology 12 DOID:65
MeSH 42 D003240
NCIt 47 C26729
UMLS 69 C0009782

Summaries for Connective Tissue Disease

MedlinePlus : 41 connective tissue is the material inside your body that supports many of its parts. it is the "cellular glue" that gives your tissues their shape and helps keep them strong. it also helps some of your tissues do their work. cartilage and fat are examples of connective tissue. there are over 200 disorders that impact connective tissue. some, like cellulitis, are the result of an infection. injuries can cause connective tissue disorders, such as scars. others, such as ehlers-danlos syndrome, marfan syndrome, and osteogenesis imperfecta, are genetic. still others, like scleroderma, have no known cause. each disorder has its own symptoms and needs different treatment.

MalaCards based summary : Connective Tissue Disease, also known as connective tissue diseases, is related to hepatitis and rheumatoid arthritis, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Connective Tissue Disease is ACTA2 (Actin, Alpha 2, Smooth Muscle, Aorta), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Ethanol and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and bone, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A musculoskeletal system disease that affects tissues such as skin, tendons, and cartilage.

Wikipedia : 71 A connective tissue disease is any disease that has the connective tissues of the body as a target of... more...

Related Diseases for Connective Tissue Disease

Diseases related to Connective Tissue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 417)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.7 HLA-DRB1 IFNG IL10 IL6 TNF
2 rheumatoid arthritis 30.6 CD40LG HLA-DRB1 HSPD1 IFNG IL10 IL1A
3 nonspecific interstitial pneumonia 30.2 CD40LG IFNG IL10 IL6 TNF
4 mikulicz disease 29.9 IL1A IL6 TNF
5 burns 29.9 IFNG IL10 IL6 TNF
6 choroiditis 29.8 IL10 IL6 TNF
7 nasopharyngitis 29.8 IFNG IL1A IL6 TNF
8 exophthalmos 29.8 CD40LG IFNG IL10 IL6 TNF
9 mixed connective tissue disease 12.5
10 undifferentiated connective tissue disease 12.4
11 mass syndrome 11.6
12 lysyl hydroxylase 3 deficiency 11.6
13 marden-walker syndrome 11.5
14 pulmonary fibrosis 11.0
15 dermatomyositis 11.0
16 scleritis 11.0
17 cutis laxa 11.0
18 winchester syndrome 10.9
19 crest syndrome 10.9
20 synovitis 10.9
21 lipodermatosclerosis 10.9
22 fibrodysplasia ossificans progressiva 10.8
23 pulmonary hypertension, familial primary, 1, with or without hht 10.6
24 aortic aneurysm, familial thoracic 1 10.6
25 arterial tortuosity syndrome 10.6
26 funisitis 10.6
27 ossification of the posterior longitudinal ligament of spine 10.6
28 ainhum 10.6
29 epidermolysis bullosa 10.6
30 mounier-kuhn syndrome 10.6
31 perniosis 10.6
32 nystagmus, congenital motor, autosomal recessive 10.5 FBN1 HLA-DRB1 TNF
33 pyridoxal 5'-phosphate-dependent epilepsy 10.5 IL10 TNF
34 angiomatosis, diffuse corticomeningeal, of divry and van bogaert 10.5 HLA-DRB1 IL6 TNF
35 distal trisomy 14q 10.5 HLA-DRB1 IFNG TNF
36 transient tic disorder 10.5 IL10 IL6 TNF
37 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.5 IFNG IL10 TNF
38 congenital hypothyroidism 10.5 CD40LG IL10 TNF
39 dextrocardia 10.5 CD40LG IL6 TNF
40 myofibroma 10.5 HLA-DRB1 IFNG IL10
41 hypoparathyroidism-retardation-dysmorphism syndrome 10.5 IL10 IL6 TNF
42 plantar wart 10.5 IFNG IL10 TNF
43 human immunodeficiency virus infectious disease 10.5 CD40LG HLA-DRB1 IL6 TNF
44 cryptococcosis 10.5 CD40LG HLA-DRB1 IL10 TNF
45 trichomalacia 10.5 IL10 IL6 TNF
46 centronuclear myopathy 5 10.5 CD40LG IFNG IL10
47 anal paget's disease 10.5 IL1A IL6 TNF
48 osteodysplasty precocious of danks mayne and kozlowski 10.5 IFNG IL10 TNF
49 phlyctenulosis 10.5 IL10 IL6 TNF
50 parkinson disease 11 10.5 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Connective Tissue Disease:



Diseases related to Connective Tissue Disease

Symptoms & Phenotypes for Connective Tissue Disease

UMLS symptoms related to Connective Tissue Disease:


back pain, muscle cramp, sciatica, musculoskeletal symptom, joint symptom

MGI Mouse Phenotypes related to Connective Tissue Disease:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 ACTA2 ACVRL1 BMPR2 CD40LG EDNRA FBN1
2 hematopoietic system MP:0005397 10.34 ACVRL1 ADAMTS13 BMPR2 CD40LG EDNRA FBN1
3 cellular MP:0005384 10.29 BMPR2 CD40LG CENPB EDNRA FBN1 HSPD1
4 growth/size/body region MP:0005378 10.29 ACVRL1 BMPR2 CENPB EDNRA FBN1 HSPD1
5 homeostasis/metabolism MP:0005376 10.29 ACVRL1 ADAMTS13 BMPR2 CD40LG EDNRA FBN1
6 immune system MP:0005387 10.27 ADAMTS13 BMPR2 CD40LG EDNRA FBN1 IFNG
7 mortality/aging MP:0010768 10.25 ACVRL1 ADAMTS13 BMPR2 CD40LG CENPB EDNRA
8 embryo MP:0005380 10.13 IFNG IL10 TNF ACVRL1 BMPR2 EDNRA
9 muscle MP:0005369 10.11 HSPD1 IFNG IL10 IL6 SPP1 TNF
10 integument MP:0010771 10.09 FBN1 IFNG IL10 IL1A IL6 SPP1
11 craniofacial MP:0005382 10.08 IFNG IL10 SPP1 TNF ACVRL1 EDNRA
12 nervous system MP:0003631 10.06 ACVRL1 BMPR2 CD40LG EDNRA FBN1 HSPD1
13 renal/urinary system MP:0005367 9.86 ACVRL1 BMPR2 CD40LG EDNRA FBN1 IFNG
14 reproductive system MP:0005389 9.81 CD40LG CENPB FBN1 HSPD1 IFNG IL10
15 respiratory system MP:0005388 9.65 TNF ACVRL1 BMPR2 EDNRA FBN1 IFNG
16 skeleton MP:0005390 9.28 BMPR2 CD40LG EDNRA FBN1 IFNG IL10

Drugs & Therapeutics for Connective Tissue Disease

Drugs for Connective Tissue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 993)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2 64-17-5 702
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
3
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 23214-92-8 31703
4
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
5
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
6
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 104987-11-3 445643 439492
7
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
8
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
9
Etoposide Approved Phase 4,Phase 3,Phase 1,Phase 2 33419-42-0 36462
10
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 15663-27-1 84093 441203 2767
11
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
12
Tamoxifen Approved Phase 4,Phase 2,Phase 1 10540-29-1 2733526
13
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 51-43-4 5816
14
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
15
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
16
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
17
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
18
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2 15307-86-5 3033
19
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
20
Sulfasalazine Approved Phase 4,Phase 3,Phase 2 599-79-1 5353980 5359476
21
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 9004-61-9 53477741 24759
22
Atenolol Approved Phase 4,Phase 3,Phase 2 29122-68-7 2249
23
Aminolevulinic acid Approved Phase 4 106-60-5 137
24
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
25
Goserelin Approved Phase 4,Phase 3 65807-02-5 47725 5311128
26
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 331731-18-1 16219006
27
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
28
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
29
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 1 378-44-9 9782
30
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1 170277-31-3
31
Bosentan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147536-97-8 104865
32
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1 118-42-3 3652
33
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
34
Ifosfamide Approved Phase 4,Phase 2,Phase 3,Phase 1 3778-73-2 3690
35
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-24-8 5755
36
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
37
Calcium carbonate Approved Phase 4,Phase 3,Phase 2 471-34-1
38
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 137-58-6 3676
39
Desogestrel Approved Phase 4 54024-22-5 40973
40
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
41
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-75-2 4033
42
Nandrolone Approved, Experimental, Illicit Phase 4 434-22-0, 62-90-8 9904 229455
43
Leflunomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75706-12-6 3899
44
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
45
Sulfamethoxazole Approved Phase 4,Phase 2,Phase 3 723-46-6 5329
46
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 2 202409-33-4 123619
47
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 16590-41-3 5360515
48
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1 332348-12-6 10237
49
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
50
Trimethoprim Approved, Vet_approved Phase 4,Phase 2,Phase 3 738-70-5 5578

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis Unknown status NCT01042158 Phase 4
3 Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan Unknown status NCT01051960 Phase 4
4 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4
5 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4
6 The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis Unknown status NCT02480335 Phase 4
7 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4
8 An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst Unknown status NCT02154789 Phase 4
9 Keloid Scarring: Treatment and Pathophysiology Unknown status NCT01295099 Phase 4
10 A Randomized Clinical Study Comparing Two Closure Techniques of Excised Keloids Unknown status NCT00519493 Phase 4
11 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
12 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4
13 Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent. Unknown status NCT01835613 Phase 4
14 TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4
15 Bucillamine Study of Holding Remission After Infliximab Dose-off Unknown status NCT00716248 Phase 4
16 Hanyang University Medical Center Arthritis Network Unknown status NCT00418405 Phase 4
17 Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis Unknown status NCT00291915 Phase 4
18 Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis Unknown status NCT02275299 Phase 4
19 Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4
20 Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis Unknown status NCT00573651 Phase 4
21 Remission Induction in Very Early Rheumatoid Arthritis Unknown status NCT00523692 Phase 4
22 Rheumatoid Arthritis Patients in Training Unknown status NCT00434200 Phase 4
23 Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI Unknown status NCT01893151 Phase 4
24 Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis Unknown status NCT01282528 Phase 4
25 Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis Unknown status NCT00216177 Phase 4
26 REstore Working Ability in RheumatoiD Arthritis Unknown status NCT01405326 Phase 4
27 Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE) Unknown status NCT01303874 Phase 4
28 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis Unknown status NCT02087696 Phase 4
29 Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine Unknown status NCT01980836 Phase 4
30 Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA) Unknown status NCT01067430 Phase 4
31 Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis Unknown status NCT01000441 Phase 4
32 MyoSure Hysteroscopic Tissue Removal System Registry Study Unknown status NCT01369758 Phase 4
33 High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids Unknown status NCT01239641 Phase 4
34 Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin Unknown status NCT01738724 Phase 4
35 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4
36 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4
37 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
38 Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate Unknown status NCT01270035 Phase 4
39 A Randomised Single Centre Study to Compare the Long-Term Wear Characteristics of Marathon™ and Enduron™ Polyethylene Cup Liners in Primary Total Hip Replacement Unknown status NCT00208442 Phase 4
40 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4
41 Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes Unknown status NCT02236481 Phase 4
42 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4
43 Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4
44 Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar® Unknown status NCT00828997 Phase 4
45 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4
46 Influenza Vaccination in Patients With Scleroderma Unknown status NCT01002508 Phase 4
47 Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis Unknown status NCT01002716 Phase 4
48 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4
49 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
50 Connective Tissue Graft Versus Mucograft Collagen Matrix for Coverage of Multiple Gingival Recession Defects Unknown status NCT01440426 Phase 4

Search NIH Clinical Center for Connective Tissue Disease

Cochrane evidence based reviews: connective tissue diseases

Genetic Tests for Connective Tissue Disease

Genetic tests related to Connective Tissue Disease:

id Genetic test Affiliating Genes
1 Abnormality of Connective Tissue 29

Anatomical Context for Connective Tissue Disease

MalaCards organs/tissues related to Connective Tissue Disease:

39
Lung, Skin, Bone, T Cells, Heart, Endothelial, Breast

Publications for Connective Tissue Disease

Articles related to Connective Tissue Disease:

(show top 50) (show all 1077)
id Title Authors Year
1
Successful treatment of Type B insulin resistance with mixed connective tissue disease by pulse glucocorticoids and cyclophosphamide. ( 28084020 )
2017
2
Microparticle subpopulations are potential markers of disease progression and vascular dysfunction across a spectrum of connective tissue disease. ( 28053878 )
2017
3
Autoantibody to scaffold attachment factor B (SAFB): A novel connective tissue disease-related autoantibody associated with interstitial lung disease. ( 27682649 )
2017
4
Connective tissue disease: Reflections on the EULAR recommendations for the treatment of systemic sclerosis. ( 28053333 )
2017
5
Inhibition of endocan attenuates monocrotaline-induced connective tissue disease related pulmonary arterial hypertension. ( 27912147 )
2017
6
The correlation between miR-200c and the severity of interstitial lung disease associated with different connective tissue diseases. ( 27309544 )
2017
7
Long-term outcome in juvenile-onset mixed connective tissue disease: a nationwide Norwegian study. ( 27283334 )
2016
8
Evaluation of computer-based computer tomography stratification against outcome models in connective tissue disease-related interstitial lung disease: a patient outcome study. ( 27876024 )
2016
9
Undifferentiated connective tissue disease and interstitial lung disease: Trying to define patterns. ( 27979657 )
2016
10
A case of idiopathic portal hypertension associated with nodular regenerative hyperplasia-like nodule of the liver and mixed connective tissue disease. ( 27151480 )
2016
11
Undifferentiated Connective Tissue Disease, Mixed Connective Tissue Disease, and Overlap Syndromes in Rheumatology. ( 27311225 )
2016
12
Mixed connective tissue disease-enigma variations? ( 27436003 )
2016
13
Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. ( 27060110 )
2016
14
Prevalence of mixed connective tissue disease in a population-based registry of American Indian/Alaska Native people in 2007. ( 27788293 )
2016
15
Pauci-Immune Crescentic Glomerulonephritis in Connective Tissue Disease. ( 27504208 )
2016
16
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. ( 28039187 )
2016
17
Abnormalities in lung volumes and airflow in children with newly diagnosed connective tissue disease. ( 26676969 )
2016
18
SY 11-4 CONNECTIVE TISSUE DISEASE AND ITS ASSOCIATION WITH ARTERIAL HYPERTENSION. ( 27643119 )
2016
19
Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. ( 27644575 )
2016
20
Mixed connective tissue disease with bilateral erythematous palpebral oedema and targetoid skin lesions. ( 27694069 )
2016
21
Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. ( 26762710 )
2016
22
The illness experience of youth with lupus/mixed connective tissue disease: a mixed methods analysis of patient and parent perspectives. ( 27125290 )
2016
23
Connective tissue disease-related pulmonary arterial hypertension. ( 27421214 )
2016
24
A case of mixed connective tissue disease. ( 27728674 )
2016
25
Management of interstitial lung disease associated with connective tissue disease. ( 26912511 )
2016
26
Immunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndrome. ( 27826173 )
2016
27
CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc). ( 27650429 )
2016
28
Successful Immunosuppressive Treatment of Mixed Connective Tissue Disease Complicated by Microscopic Polyangiitis. ( 27238624 )
2016
29
Autoantibodies Are Already Found in Connective Tissue Disease-Associated Interstitial Lung Disease. ( 27613986 )
2016
30
Linear atrophoderma of Moulin: a disease related to immunity or a kind of connective tissue disease? ( 27283080 )
2016
31
Pediatric Mixed Connective Tissue Disease. ( 27032791 )
2016
32
The wound/burn guidelines - 4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis. ( 26972733 )
2016
33
Comment on: rituximab in autoimmune connective tissue disease-associated interstitial lung disease. ( 27550303 )
2016
34
Adhesive arachnoiditis in mixed connective tissue disease: a rare neurological manifestation. ( 27986694 )
2016
35
Invasive pulmonary fungal infections in patients with connective tissue disease: a retrospective study from northern China. ( 27683823 )
2016
36
Rituximab for the treatment of connective tissue disease-associated interstitial lung disease. ( 26847096 )
2016
37
Epidemiology of Mixed Connective Tissue Disease 1985-2014: A Population Based Study. ( 26946215 )
2016
38
Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study. ( 26758437 )
2016
39
Connective tissue disease-related interstitial lung disease. ( 27421215 )
2016
40
The risk of cancer in patients with connective tissue diseases but without dermatomyositis or polymyositis: A multicenter cohort study conducted over 15 years in China. ( 27474413 )
2016
41
Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children. ( 27738519 )
2016
42
Aberrant expression of cytokine interleukin 9 along with interleukin 4 and interferon I^ in connective tissue disease-associated interstitial lung disease: association with severity of pulmonary fibrosis. ( 26925124 )
2016
43
Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study. ( 27094018 )
2016
44
Initial presentation and outcome of pediatric-onset mixed connective tissue disease: A French multicenter retrospective study. ( 26677987 )
2016
45
Lung cancer development in patients with connective tissue disease-related interstitial lung disease: A retrospective observational study. ( 27977621 )
2016
46
Mixed connective tissue disease. ( 27421219 )
2016
47
The high incidence of anti-Ro/SSA and anti-p200 antibodies in female patients with connective tissue diseases confirms the importance of screening for congenital heart block-associated autoantibodies during pregnancy. ( 26830903 )
2016
48
SY 11-4 CONNECTIVE TISSUE DISEASE AND ITS ASSOCIATION WITH ARTERIAL HYPERTENSION. ( 27754164 )
2016
49
Clinical association of mixed connective tissue disease and granulomatosis with polyangiitis: a case report and systematic screening of anti-U1RNP and anti-PR3 auto-antibody double positivity in ten European hospitals. ( 27618831 )
2016
50
Application of SLICC classification criteria in undifferentiated connective tissue disease and evolution in systemic lupus erythematosus: analysis of a large monocentric cohort with a long-term follow-up. ( 27703051 )
2016

Variations for Connective Tissue Disease

ClinVar genetic disease variations for Connective Tissue Disease:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 ACTA2 NM_001613.2(ACTA2): c.536G> A (p.Arg179His) single nucleotide variant Pathogenic rs387906592 GRCh37 Chromosome 10, 90701066: 90701066

Expression for Connective Tissue Disease

Search GEO for disease gene expression data for Connective Tissue Disease.

Pathways for Connective Tissue Disease

Pathways related to Connective Tissue Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 ACTA2 ACVRL1 BMPR2 CD40LG FBN1 IL10
2
Show member pathways
13.66 ACVRL1 BMPR2 CD40LG EDNRA IFNG IL10
3
Show member pathways
13.4 ACTA2 ACVRL1 BMPR2 CD40LG IL10 IL1A
4
Show member pathways
13.37 CD40LG HLA-DRB1 IFNG IL10 IL1A IL6
5
Show member pathways
13.28 ACTA2 ACVRL1 BMPR2 CD40LG IL10 IL1A
6
Show member pathways
12.92 IFNG IL10 IL6 SFTPD SPP1 TNF
7
Show member pathways
12.79 HLA-DRB1 IFNG IL1A IL6 TNF
8
Show member pathways
12.71 CD40LG IL1A IL6 TNF TNFSF13B
9
Show member pathways
12.65 CD40LG HLA-DRB1 HSPD1 IFNG IL10 IL1A
10
Show member pathways
12.64 CD40LG HLA-DRB1 IFNG IL10 TNF
11
Show member pathways
12.6 HLA-DRB1 IFNG IL10 IL1A IL6 TNF
12 12.55 CD40LG IFNG IL10 TNF TNFSF13B
13
Show member pathways
12.43 CD40LG IFNG IL10 IL1A IL6 TNF
14
Show member pathways
12.27 IFNG IL1A IL6 TNF
15
Show member pathways
12.23 CD40LG HLA-DRB1 IFNG IL10 IL1A TNF
16
Show member pathways
12.19 IFNG IL6 SFTPD TNF
17 12.19 HSPD1 IL10 IL1A IL6 TNF
18
Show member pathways
12.16 IFNG IL10 IL1A IL6 TNF
19 12.09 BMPR2 IFNG IL1A TNF
20 12.01 IFNG IL10 IL6 TNF
21 12 IFNG IL1A IL6 TNF TNFSF13B
22 11.99 IL10 IL1A IL6 TNF
23
Show member pathways
11.96 IFNG IL10 IL6 TNF
24 11.9 HLA-DRB1 IL1A IL6 TNF
25 11.89 IFNG IL10 IL6 TNF
26
Show member pathways
11.82 CD40LG TNF TNFSF13B
27 11.81 BMPR2 IFNG TNF
28 11.78 IFNG IL10 TNF
29 11.78 IFNG IL10 IL6 TNF
30 11.77 IL10 IL1A IL6 TNF
31
Show member pathways
11.76 CD40LG IFNG TNF
32 11.75 HLA-DRB1 HSPD1 IFNG IL10 IL1A IL6
33
Show member pathways
11.74 CD40LG TNF TNFSF13B
34 11.7 IFNG IL10 IL6
35 11.68 CD40LG IL10 IL6 TNF TNFSF13B
36 11.67 IL6 SPP1 TNF
37 11.62 IFNG SPP1 TNF
38 11.6 HSPD1 IL6 TNF
39
Show member pathways
11.6 CD40LG IFNG